Review · United States
GHRP-6
Reviewed on
Approval and product status
No FDA-approved human GHRP-6 product was identified in the checked U.S. databases as of August 30, 2026
FDA's identity record describes the GHRP-6 molecule, not a finished drug product. FDA lists GHRP-6 in compounding safety reviews and in its current 503A category list. Products sold online or made by a compounder need separate proof of identity, quality, and approval.
What was measured in people?
- Health results · Unclear
- Small studies measured short-term hormone responses. They did not establish muscle gain, fat loss, recovery, or other lasting health outcomes.
- Body changes · Moderate
- Small studies in healthy men show a short-term growth-hormone response. One small early study measured how GHRP-6 moved through the body.
A change in a hormone or body signal does not by itself prove a health benefit.
Important limits
This tool is not an independent medical review. It does not recommend treatment.
FDA lists GHRP-6 among substances that may present safety risks in compounding. FDA notes possible immune reactions from peptide impurities or aggregation, limited safety information, and possible cortisol or blood-sugar effects. This guide gives no dosing, injection, sourcing, or treatment instructions.
Still unknown: These studies do not show that GHRP-6 builds muscle, burns fat, speeds recovery, slows aging, or treats a health condition. The studies were small, short, and mainly in healthy men. One study changed the body's GHRH signal to test how the hormone response works. It was not a treatment study. No FDA-approved human GHRP-6 product was identified in the checked U.S. databases as of August 30, 2026. This is a dated database finding, not a claim about every country or future record.
This record cannot check a package, seller, batch, or personal treatment. It does not provide sport clearance.
Approval fact checks
“GHRP-6 is FDA-approved in the United States.”
Misleading. No FDA-approved human GHRP-6 product was identified in the checked U.S. databases as of August 30, 2026. FDA's substance identity record does not mean approval. This is a dated database finding, not a claim about every country or future record.
Applies to: U.S. human drug records checked on August 30, 2026.
“A compounded GHRP-6 product is FDA-approved.”
Misleading. FDA says it does not approve compounded drugs. Its current 503A list puts GHRP-6 in Category 3. This means the nomination did not have enough support. FDA also lists safety concerns for 503B compounding. A 2019 warning letter said GHRP-6 did not meet the 503A rules in that case.
Applies to: U.S. FDA records about compounded GHRP-6, checked August 30, 2026. This is not legal advice about one product.
Cited sources (5)
- U.S. Food and Drug Administration: Bulk drug substances used in compounding under section 503A
- U.S. Food and Drug Administration: 503A Category 3 bulk drug substances nominated without adequate support
- U.S. Food and Drug Administration: Bulk drug substances that may present significant compounding safety risks
- U.S. Food and Drug Administration: United Pharmacy warning letter
- U.S. Food and Drug Administration: Human drug compounding: FDA questions and answers
Products in this review
These are selected records, not every product or form.
No product label record is included here. That is not a separate approval decision. Read the status and sources above.
What the research shows
Small human studies show short-term hormone effects. In 17 healthy men, GHRP-6 increased growth hormone for a short time. Another study in 9 healthy men found that blocking a body signal called GHRH greatly reduced the response. An early study in 9 healthy men measured GHRP-6 exposure in the body. These studies measured hormones and exposure, not muscle gain, fat loss, recovery, or long-term health.
Read all GHRP-6 fact checksSources used in this review
A source may support some statements, not all of them. Use the links above or this review to see what each source supports.
Show 11 sources
- GHRP-6 substance identity record (UNII 4H7N4I6X6A)
U.S. Food and Drug Administration Global Substance Registration System · Reference · 2026
Source accessed
- Growth hormone response to GHRP-6 in healthy men
PubMed · Human pharmacology · 1989
Source accessed
- GHRP-6 growth hormone response and GHRH dependence
PubMed · Human pharmacology · 1998
Source accessed
- GHRP-6 exposure study in healthy men
PubMed · Human pharmacology · 2012
Source accessed
- Drug approvals and databases
U.S. Food and Drug Administration · Regulatory · 2026
Source accessed
- Bulk drug substances used in compounding under section 503A
U.S. Food and Drug Administration · Regulatory · 2026
Source accessed
- 503A Category 3 bulk drug substances nominated without adequate support
U.S. Food and Drug Administration · Regulatory · 2026
Source accessed
- Bulk drug substances that may present significant compounding safety risks
U.S. Food and Drug Administration · Regulatory · 2026
Source accessed
- United Pharmacy warning letter
U.S. Food and Drug Administration · Regulatory · 2019
Source accessed
- Human drug compounding: FDA questions and answers
U.S. Food and Drug Administration · Regulatory · 2026
Source accessed
- 2026 Prohibited List
World Anti-Doping Agency · Anti-doping · 2026
Source accessed